 Company decision follows observation of asymptomatic liver transaminitis in two subjects enrolled in first dose cohort of 200mg BID Evidence of clinical activity observed; full data set to be presented at upcoming scientific conference Multiple chemically distinct, next-generation oral KIT inhibitors in exploratory toxicology studies; on track to nominate development candidate in ... The post Third Harmonic Bio Announces Discontinuation of Phase 1b Study of THB001 in Chronic Inducible Urti... 